• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Pyxis Oncology Inc.

    4/14/25 4:05:55 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001579781
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Pyxis Oncology, Inc.
    SEC File Number
    001-40881
    Address of Issuer
    321 HARRISON AVENUE
    BOSTON
    MASSACHUSETTS
    02118
    Phone
    (617) 221-9059
    Name of Person for Whose Account the Securities are To Be Sold
    HUMPHREY RACHEL
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    14001361.966159041504/14/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/26/2025Restricted Stock VestingIssuerCheckbox not checked140003/26/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/14/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    12/05/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Rachel Humphrey

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PYXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    More analyst ratings

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

      - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul

      5/15/25 7:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Participate in Two Upcoming Investor Conferences

      BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th

      5/14/25 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

      Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu

      4/25/25 1:17:47 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

      BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel

      3/13/24 8:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

      Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.

      12/19/23 9:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/12/24 11:53:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/6/24 4:36:24 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

      SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      4/3/24 5:10:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pyxis Oncology downgraded by William Blair

      William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

      11/21/24 7:55:42 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Pyxis Oncology with a new price target

      Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00

      11/8/24 8:24:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Pyxis Oncology with a new price target

      Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00

      8/8/24 6:48:55 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      11/27/24 5:09:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/28/23 4:32:03 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/27/23 6:37:45 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pyxis Oncology Inc.

      10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:41:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:35:33 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.

      SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      5/6/25 4:17:33 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

      - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

      11/12/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

      - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

      8/14/24 4:05:00 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

      PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom

      5/14/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care